

Special Issue

Advances in Papillary Thyroid Cancer Research

Message from the Guest Editor

Papillary thyroid cancer (PTC) accounts for more than 80% of all thyroid carcinomas, and patients face a good prognosis with a 10-year overall survival exceeding 90%. The incidence is increasing, but still considered low compared to other cancers; however, due to the excellent prognosis, the prevalence is relatively high. Curative treatment consists of thyroid surgery, total thyroidectomy or lobectomy in some cases, and radioactive iodine treatment when implied. These sometimes life-long treatments might influence a large number of patients negatively, and it is therefore of great importance not to overtreat patients. In this Special Issue we would like to discuss further how we can individualize treatment for PTC patients depending on the specific characteristics of the tumor, and from that decide which treatment will be most efficient. In addition, new treatment modalities focusing on PTC subgroups or approaches for small indolent cancers with a “watch and wait” approach will be of interest.

Guest Editor

Dr. Catharina Ihre Lundgren
Karolinska Institutet, Stockholm, Sweden

Deadline for manuscript submissions

closed (15 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/127071

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)